The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Jonathan W. Friedberg, Julie M. Vose, Jennifer L. Kelly, Faith Young, Steven H. Bernstein, Derick Peterson, Lynn Rich, Susan Blumel, Nicole K. Proia, Jane Liesveld, Richard I. Fisher, James O. Armitage, Steven Grant, John P. Leonard

Research output: Contribution to journalArticlepeer-review

166 Scopus citations

Fingerprint

Dive into the research topics of 'The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds